WSWoong-Kyung Suh

Woong-Kyung Suh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Woong-Kyung Suh has a total of 237 co-authors. Here are the top co-authors by number of shared publications:

  • Jinsam Chang

    Institut de recherches cliniques de Montréal

    8 shared publications
  • Mariko Witalis

    Institut de recherches cliniques de Montréal

    6 shared publications
  • Andrew Wakeham

    Campbell Family Institute for Breast Cancer Research and Ontario Cancer Institute, Toronto, Ontario, Canada M5G 2C1,1 Department of Biomolecular Sciences, Faculty of Medicine, Saga University, Saga, Japan,2 Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Canada L8N 3Z5,3 Departments of Immunology,4 Medical Biophysics, University of Toronto, Toronto, Ontario, Canada M5S 1A85

    5 shared publications
  • Hitoshi Okada

    Department of Immunology, Unit 902, The University of Texas MD Anderson Cancer Center, 7455 Fannin Street, Houston, TX 77054, USA

    5 shared publications
  • Joanna Li

    Institut de recherches cliniques de Montréal

    5 shared publications
  • Joanne Leung

    Institut de Recherches Cliniques de Montréal, Montréal, Québec H2W 1R7, Canada

    5 shared publications

Latest Publications

  • Open Access

    Identification of a neoplastic Tfh-like cellular subset in a mouse model of angioimmunoblastic T cell lymphoma

    by Saba Mohammaei, Jiyeon Lee, Antoine Bouchard, Evany Bernal Ballesteros, Nikoletta Diamantopoulos, Lifei Hou, Eileen Remold, Junhun Cho, Woong-Kyung Suh

    Background: Nodal T-follicular helper cell lymphoma, angioimmunoblastic type (nTFHL-AI, or AITL), is an aggressive peripheral T cell lymphoma without effective treatments. It has been shown that genetic and epigenetic changes lead to the expansion of neoplastic CD4 + T cells originating from T follicular helper (Tfh) cells, which subsequently cause B cell expansion and tumor development. However, it remains unclear if the Tfh-like cell populations contain a subset that drives tumor progression and, if so, whether such a subset may have druggable targets. Methods: Through single-cell transcriptome analysis of Tfh-like cells isolated from the spontaneously arising AITL-like tumors in Roquin san/+ mice, we identified and characterized a tumor-enriched Tfh cell subset highly expressing CXCR6 and IL-18 receptor, termed “Double-Expressor (DE) Tfh” cells. Using genetic or pharmacological approaches, we depleted DE Tfh cells in vivo and monitored tumor size (by ultrasound imaging) and the status of DE Tfh subset (by flow cytometry). We performed NanoString gene expression profiling of AITL patient samples to identify AITL cases that are relevant to Roquin san/+ mouse model. Results: DE Tfh cells expressed higher levels of Ki-67 and enhancer of zeste homolog 2 (EZH2) and proliferated more rapidly compared to other Tfh cells in an IL-18 and EZH2 dependent manner. Furthermore, DE Tfh cells engrafted better than non-DE Tfh cells and could cause B cell expansion when adoptively transferred into lymphopenic recipients. On the other hand, depletion of DE Tfh cells via Ezh2 gene deletion, inhibition of EZH2 (using FDA-approved drug, tazemetostat), or anti-CXCR6 mAb led to tumor regression. These findings may be relevant to a subset of human AITL cases since we found that ~20-30% of AITL patient samples have concomitantly elevated expression of CXCR6 , IL-18R1 , and IFNG . Conclusions: Our study identified a pathogenic Tfh-like subset essential for AITL tumor progression in a mouse model and suggests that identifying and targeting a DE Tfh-like subset in AITL patients might be an effective strategy.


  • A Dock8-dependent mechanosensitive central actin pool maintains T cell shape and protects nucleus during migration

    by Connie Shen, Aysha Cerf, Jérémy Postat, Aanya Bhagrath, Mauricio Merino, Angela Mingarelli, Grace Barnes, Dhanesh Patel, Dakota Rogers, Vincent M. Luo, et al.

    Immune cells navigate through complex tissue architectures by extensive cellular deformation, low adhesion, and high cell velocities. Loss-of-function mutations in Dedicator of Cytokinesis 8 ( Dock8 ) are associated with immunodeficiency as immune cells becoming entangled during migration through dense environments, but their migration on two-dimensional surfaces remains entirely intact. Here we investigated the specific cytoskeletal defect of Dock8 -deficient activated T cells and describe a central pool of F-actin in wild-type murine and human T cells that is absent in Dock8 knockout T cells. The appearance of the central actin pool is mechanoresponsive and emerges only when cells are very confined. We identified mammalian sterile 20-like (Mst1) as a necessary component in this mechanosensitive pathway in addition to Dock8, allowing for cell shape integrity and survival during migration through complex environments. Our work shows that loss of the central actin pool results in greater nuclear deformation, accrual of DNA damage, and premature cell senescence.


  • ICOS-expressing Regulatory T Cells Influence the Composition of Antitumor CTL Populations

    by Nikoletta Diamantopoulos, Joanna Li, Antoine Bouchard, Loick Joumier, Saba Mohammaei, Vincent Panneton, Jinsam Chang, Mohan Malleshaiah, Woong-Kyung Suh

    The role of ICOS in antitumor T cell responses and overall tumor progression has been controversial. In this study, we compared tumor progression in mice lacking ICOS selectively in regulatory T (Treg) cells or in all T cells. Using an experimental melanoma lung metastasis model, we found that Treg cell–specific ICOS knockout reduces the overall tumor burden compared with Cre control mice, with increased CD4+-to-Treg cell and CD8+-to-Treg cell ratios in the tumor. In contrast, there was no difference in the tumor burden in mice lacking ICOS in all of the T cell compartments. This suggests a dual role of ICOS costimulation in promoting protumor and antitumor T cell responses. Consistent with reduced tumor burden, we found that Treg cell–specific deletion of ICOS leads to an increase of CD8+ CTLs that express high levels of granzyme B and perforin. Moreover, single-cell transcriptome analysis revealed an increase of Ly108+Eomeshi CD8+ T cells at the cost of the Ly108+T-bethi subset in Treg cell–specific knockout mice. These results suggest that ICOS-expressing Treg cells suppress the CTL maturation process at the level of Eomes upregulation, a critical step known to drive perforin expression and cytotoxicity. Collectively, our data imply that cancer immunotherapies using ICOS agonist Abs may work better in Treg cell–low tumors or when they are combined with regimens that deplete tumor-infiltrating Treg cells.


  • Open Access

    ICOS costimulation is indispensable for the differentiation of T follicular regulatory cells

    by Vincent Panneton, Barbara C Mindt, Yasser Bouklouch, Antoine Bouchard, Saba Mohammaei, Jinsam Chang, Nikoletta Diamantopoulos, Mariko Witalis, Joanna Li, Albert Stancescu, et al.

    ICOS is a T-cell costimulatory receptor critical for Tfh cell generation and function. However, the role of ICOS in Tfr cell differentiation remains unclear. Using Foxp3-Cre–mediated ICOS knockout (ICOS FC) mice, we show that ICOS deficiency in Treg-lineage cells drastically reduces the number of Tfr cells during GC reactions but has a minimal impact on conventional Treg cells. Single-cell transcriptome analysis of Foxp3+cells at an early stage of the GC reaction suggests that ICOS normally inhibitsKlf2expression to promote follicular features includingBcl6up-regulation. Furthermore, ICOS costimulation promotes nuclear localization of NFAT2, a known driver of CXCR5 expression. Notably, ICOS FC mice had an unaltered overall GC B-cell output but showed signs of expanded autoreactive B cells along with elevated autoantibody titers. Thus, our study demonstrates that ICOS costimulation is critical for Tfr cell differentiation and highlights the importance of Tfr cells in maintaining humoral immune tolerance during GC reactions.


  • ICOS-Deficient Regulatory T Cells Can Prevent Spontaneous Autoimmunity but Are Impaired in Controlling Acute Inflammation

    by Jinsam Chang, Antoine Bouchard, Yasser Bouklouch, Vincent Panneton, Joanna Li, Nikoletta Diamantopoulos, Saba Mohammaei, Roman Istomine, Fernando Alvarez, Ciriaco A Piccirillo, et al.

    ICOS is induced in activated T cells and its main role is to boost differentiation and function of effector T cells. ICOS is also constitutively expressed in a subpopulation of Foxp3+ regulatory T cells under steady-state condition. Studies using ICOS germline knockout mice or ICOS-blocking reagents suggested that ICOS has supportive roles in regulatory T (Treg) cell homeostasis, migration, and function. To avoid any compounding effects that may arise from ICOS-deficient non–Treg cells, we generated a conditional knockout system in which ICOS expression is selectively abrogated in Foxp3-expressing cells (ICOS FC mice). Compared to Foxp3-Cre control mice, ICOS FC mice showed a minor numerical deficit of steady-state Treg cells but did not show any signs of spontaneous autoimmunity, indicating that tissue-protective Treg populations do not heavily rely on ICOS costimulation. However, ICOS FC mice showed more severe inflammation in oxazolone-induced contact hypersensitivity, a model of atopic dermatitis. This correlated with elevated numbers of inflammatory T cells expressing IFN-γ and/or TNF-α in ICOS FC mice compared with the control group. In contrast, elimination of ICOS in all T cell compartments negated the differences, confirming that ICOS has a dual positive role in effector and Treg cells. Single-cell transcriptome analysis suggested that ICOS-deficient Treg cells fail to mature into T-bet+CXCR3+ “Th1-Treg” cells in the draining lymph node. Our results suggest that regimens that preferentially stimulate ICOS pathways in Treg cells might be beneficial for the treatment of Th1-driven inflammation. Key Points ICOS-deficient Treg cells can suppress spontaneous autoimmunity. ICOS-deficient Treg cells show impaired differentiation of Th1-Treg cells.


  • Open Access

    The ICOS–ICOSL pathway tunes thymic selection

    by Mengqi Dong, Jinsam Chang, Marie‐Ève Lebel, Noémie Gervais, Marilaine Fournier, Ève Mallet Gauthier, Woong‐Kyung Suh, Heather J Melichar

    Negative selection of developing T cells plays a significant role in T‐cell tolerance to self‐antigen. This process relies on thymic antigen‐presenting cells which express both self‐antigens and cosignaling molecules. Inducible T‐cell costimulator (ICOS) belongs to the CD28 family of cosignaling molecules and binds to ICOS ligand (ICOSL). The ICOS signaling pathway plays important roles in shaping the immune response to infections, but its role in central tolerance is less well understood. Here we show that ICOSL is expressed by subsets of thymic dendritic cells and medullary thymic epithelial cells as well as thymic B cells. ICOS expression is upregulated as T cells mature in the thymus and correlates with T‐cell receptor signal strength during thymic selection. We also provide evidence of a role for ICOS signaling in mediating negative selection. Our findings suggest that ICOS may fine‐tune T‐cell receptor signals during thymic selection contributing to the generation of a tolerant T‐cell population.


  • Open Access

    ICOS costimulation is indispensable for the differentiation of T follicular regulatory cells

    by Vincent Panneton, Barbara C. Mindt, Yasser Bouklouch, Antoine Bouchard, Saba Mohammaei, Jinsam Chang, Mariko Witalis, Joanna Li, Albert Stancescu, John E. Bradley, et al.

    ICOS is a T cell costimulatory receptor critical for Tfh cell generation and function. However, the role of ICOS in Tfr cell differentiation remains unclear. Using Foxp3-Cre-mediated ICOS knockout (ICOS FC) mice, we show that ICOS deficiency in Treg-lineage cells drastically reduces the number of Tfr cells during GC reactions but has a minimal impact on conventional Treg cells. Single-cell transcriptome analysis of Foxp3 + cells at an early stage of the GC reaction suggests that ICOS normally inhibits Klf2 expression to promote follicular features including Bcl6 upregulation. Further, ICOS costimulation promotes nuclear localization of NFAT2, a known driver of CXCR5 expression. Notably, ICOS FC mice had an unaltered overall GC B cell output but showed signs of expanded autoreactive B cells along with elevated autoantibody titers. Thus, our study demonstrates that ICOS costimulation is critical for Tfr cell differentiation and highlights the importance of Tfr cells in maintaining humoral immune tolerance during GC reactions.

  • Open Access

    Progression of AITL-like tumors in mice is driven by Tfh signature proteins and T-B cross talk

    by Mariko Witalis, Jinsam Chang, Ming-Chao Zhong, Yasser Bouklouch, Vincent Panneton, Joanna Li, Thorsten Buch, Seok Jin Kim, Won Seog Kim, Young Hyeh Ko, et al.

    Angioimmunoblastic T-cell lymphoma (AITL) is an aggressive peripheral T-cell lymphoma driven by a pool of neoplastic cells originating from T follicular helper (Tfh) cells and concomitant expansion of B cells. Conventional chemotherapies for AITL have shown limited efficacy, and as such, there is a need for improved therapeutic options. Because AITL originates from Tfh cells, we hypothesized that AITL tumors continue to rely on essential Tfh components and intimate T-cell–B-cell (T-B) interactions. Using a spontaneous AITL mouse model (Roquinsan/+ mice), we found that acute loss of Bcl6 activity in growing tumors drastically reduced tumor size, demonstrating that AITL-like tumors critically depend on the Tfh lineage–defining transcription factor Bcl6. Because Bcl6 can upregulate expression of signaling lymphocytic activation molecule–associated protein (SAP), which is known to promote T-B conjugation, we next targeted the SAP-encoding Sh2d1a gene. We observed that Sh2d1a deletion from CD4+ T cells in fully developed tumors also led to tumor regression. Further, we provide evidence that tumor progression depends on T-B cross talk facilitated by SAP and high-affinity LFA-1. In our study, AITL-like tumors relied heavily on molecular pathways that support Tfh cell identity and T-B collaboration, revealing potential therapeutic targets for AITL.


  • Open Access

    Hippo Signal Transduction Mechanisms in T Cell Immunity

    by Antoine Bouchard, Mariko Witalis, Jinsam Chang, Vincent Panneton, Joanna Li, Yasser Bouklouch, Woong-Kyung Suh

    Bouchard A, et al. Immune Netw. 2020 Oct;20(5):e36. https://doi.org/10.4110/in.2020.20.e36


  • Inducible T‐cell co‐stimulator: Signaling mechanisms in T follicular helper cells and beyond

    by Vincent Panneton, Jinsam Chang, Mariko Witalis, Joanna Li, Woong‐Kyung Suh

    Human patients with homozygous null mutations in the ICOS gene suffer from recurrent infections due to humoral immune defects. Studies on human patients and mouse models have shown that inducible T‐cell co‐stimulator (ICOS)‐deficient individuals cannot form T follicular helper (Tfh) cells, a group of CD4 T cells that migrate into B cell follicles and facilitate germinal center (GC) reactions. ICOS‐induced phosphoinositide 3‐kinase signaling pathways have been shown to play critical roles in Tfh programming, migration of Tfh cells into the GC, and delivery of T cell help during Tfh‐GC B cell conjugation. These processes are also assisted by ICOS‐mediated intracellular calcium mobilization and TANK‐binding kinase 1 signaling. However, ICOS signaling also has stimulatory roles in T regulatory cells and innate lymphoid cells (ILCs), providing another layer of complexity. In this review, we discuss cell‐type‐specific signaling mechanisms utilized by ICOS in Tfh cells, T regulatory cells, and ILCs. Whenever relevant, we compare the roles and signaling pathways of ICOS and CD28. Understanding ICOS signal transduction mechanisms used by distinct immune subsets at different stages of immune responses or disease progression may help improve vaccination protocols, treat autoimmune diseases, and enhance cancer immunotherapy.